-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 6, Hengrui Medicine issued an announcement stating that it had recently received the approval of the State Drug Administration for the issuance of the "Drug Clinical Trial Approval Notice" for Apatinib mesylate tablets
According to the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the apatinib mesylate accepted on April 25, 2021 meets the relevant requirements of drug registration, and it is agreed to be used for gastric cancer or gastroesophageal junction cancer.